Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects between 18 and 75 years of age.~2. Moderate to severe plaque-type psoriasis for at least 6 months.~3. Subject is a candidate for systemic biologic therapy.~4. Subject has IGA ≥3, involved body surface area (BSA) ≥10%, and PASI ≥12 at screening and at baseline.~5. Subject is able to comply with the study procedures.~6. Subject must provide informed consent.~Exclusion Criteria (Main):~1. Non-plaque type psoriasis, drug-induced psoriasis, or other skin conditions (e.g., eczema). (Psoriatic arthritis is allowed).~2. Other medical conditions, including planned surgery or active infection / history of infection, as defined in the study protocol. Subjects will be screened for tuberculosis and hepatitis B / hepatitis C.~3. Laboratory abnormalities at screening, as defined in the study protocol.~4. Prior use of systemic or topical treatments for psoriasis, as defined in the study protocol.~5. Prior use of any compound targeting IL-17, more than two biologic therapies, ustekinumab within 6 months, or TNF targeting therapies within 12 weeks.~6. History of suicidal thoughts within 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- M1095 (Sonelokimab) 30mg (Type: EXPERIMENTAL): M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
- M1095 (Sonelokimab) 60mg (Type: EXPERIMENTAL): M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
- M1095 (Sonelokimab) 120mg - regimen 1 (Type: EXPERIMENTAL): M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
- M1095 (Sonelokimab) 120mg - regimen 2 (Type: EXPERIMENTAL): M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
- Placebo / M1095 (Sonelokimab) 120mg (Type: PLACEBO_COMPARATOR): Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
- Secukinumab (Type: ACTIVE_COMPARATOR): Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).